Rocket Pharmaceuticals opened lower at $2.45, compared with its previous close of $2.48. In the last trading session, the stock traded between $2.37 and $2.46. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Rocket Pharmaceuticals is now worth
$ 6.86
Resulting in a loss of
$ 93.14 (93.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
70%
Hold
30%
Sell
0%
Markets Today
Today's Change
$-0.09 (-3.43%)
Day High
$2.46
Day Low
$2.37
Day Open
$2.45
Prev Close
$2.48
Volume
7,59,009
1W Return
-8.41%
1M Return
-3.62%
3M Return
-31.28%
6M Return
-33.29%
1Y Return
-26.53%
Fundamentals
Market Cap ($ Mn)
263
PE Ratio
-
PB Ratio
1.14
PEG Ratio
-
ROE
-61.28%
ROCE
-59.81%
EPS (TTM)
$1.12
Investment Returns
1 Week
-8.41%
1 Month
-3.62%
3 Months
-31.28%
6 Months
-33.29%
9 Months
-26.08%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
7Oct
Rocket Pharmaceuticals secures $150 million credit facility from Hercules Capital
Secured up to $150 million credit facility from Hercules Capital. Received $35 million at closing; up to $35 million more available at option. Additional $30 million contingent on Danon disease clinical milestone. Cash position of $283.7 million plus initial draw funds operations into Q3 2028. Facility includes warrants for Rocket’s common stock.
Rocket Pharmaceuticals reported Q2 adjusted EPS of $(0.37), missing the $0.24 estimate by 254.17%, despite a 40.32% YoY improvement in losses. Headline net income reached $123.2 million due to a $178.2 million PRV sale gain, boosting cash reserves to $283.7 million.
3mo ago
3Aug
Rocket Pharma reports safe Phase 2 data for Danon disease therapy
Rocket Pharmaceuticals confirms safe dosing of initial three patients in its pivotal Phase 2 trial for Danon disease, avoiding historical risks like TMA. The company is now working with the FDA to determine the path forward for the remaining nine patients in the single-arm study.
3mo ago
12Jun
Rocket Pharmaceuticals sells PRV for $180 million
Rocket Pharmaceuticals closed the sale of its FDA-granted Rare Pediatric Disease Priority Review Voucher for $180 million, extending its financial runway into Q2 2028. The voucher was granted in March 2026 alongside the approval of KRESLADI™ for LAD-I. Pro forma cash, cash equivalents, and investments now total approximately $322.6 million.
